secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGM Biosciences, Inc. (—)
CIK:        0001496323
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004455
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGM Biosciences halts two autoimmune programs, slashes workforce 73%
--------------------------------------------------------------------

- Halted imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) trials due to insufficient B cell depletion in Phase 1b.
- Workforce reduction of 73% to preserve cash; cash and investments $183.8M as of Dec 31, 2024.
- Evaluating internal options and strategic alternatives to maximize shareholder value.
- CEO Mary Beth Harler stated interim data did not meet high bar for success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496323/000119312525004455/0001193125-25-004455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496323/000119312525004455/d778635d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer